11/06/14 - 11:12 AM EST
New results from a study of Epizyme's leukemia drug were disclosed ahead of next month's American Society of Hematology annual meeting.READ FULL POST
11/06/14 - 09:57 AM EST
The new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.READ FULL POST
11/05/14 - 04:26 PM EST
Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more riskREAD FULL POST
11/04/14 - 01:40 PM EST
Not everyone is convinced that the new Sanofi CEO will remain committed to MannKind and its inhaled insulin Afrezza.READ FULL POST
11/04/14 - 10:22 AM EST
Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.READ FULL POST
10/29/14 - 09:16 AM EDT
Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board's support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex.READ FULL POST
10/29/14 - 07:30 AM EDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.READ FULL POST
10/27/14 - 11:02 AM EDT
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.READ FULL POST
10/22/14 - 11:52 AM EDT
But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.READ FULL POST
10/22/14 - 08:39 AM EDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.